X-Chem, Inc. is a privately held biotechnology company based in Waltham, Massachusetts, established in 2009 to apply its innovative drug discovery capabilities to the generation of novel small molecule therapeutics.
Our chemical strategy can be applied broadly to most targets in any therapeutic area, including the most challenging ones. We have built a strong team of leading experts with proven track records in innovative drug discovery and biotechnology partnering.
We have demonstrated our success both internally and with external partnerships by tackling some of the most difficult, intractable targets such as:
- protein:protein interaction (PPI)
- ubiquitin ligase
We have established collaborations with eight of the leading pharmaceutical companies in the world, including among others: Roche, AstraZeneca, Bayer and Pfizer. We also have partnerships with top tier biotechnology companies, academic centers and non-profit institutions. We have generated novel lead compounds against dozens of high-value therapeutic targets, leading to licensing of multiple lead series by our partners.
The company was founded in 2009 by industry veterans Richard Wagner, Brant Binder and Gordon Binder. In 2010, X-Chem and Pharmaceutical Product Development, LLC (PPD) formed a strategic partnership, including an investment by PPD. In September 2014, PPD exercised its option to acquire all remaining interests in X-Chem, while retaining the company’s management, scientific staff and biotechnology business model. The company was spun out as an independent company in 2015 under the ownership of the private equity firms the Carlyle Group, and Hellman and Friedman.